DIABETES drug Jardiance
(empagliflozin) from Boehringer
Ingelheim and Eli Lilly is to be
studied for the treatment of people
with chronic heart failure (CHF).
Two concurrent clinical trials will
commence within 12 months and
recruit people with CHF both with
and without type 2 diabetes.
The research follows previous
Jardiance trials which showed a
reduction in cardiovascular risk.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Apr 16
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.